Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
10-02-01 Anticholinesterases
Links
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE HST15: Onasemnogene abeparvovec for treating spinal muscular atrophy
- NICE HST24: Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NST22 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
- NICE TA588: Nusinersen for treating spinal muscular atrophy
- NICE TA588: Nusinersen for treating spinal muscular atrophy
- NICE TA755: Risdiplam for treating spinal muscular atrophy
- NICE TA755:Risdiplam for treating spinal muscular atrophy
- NICE: Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy
- NICE: Onasemnogene abeparvovec for treating spinal muscular atrophy
- NICE:Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
UKMI Q&A: Converting between Pyridostigmine & Neostigmine- UKMI Q&A: Converting between Pyridostigmine & Neostigmine